In conclusion, anti-BCMA CAR-T cells could have the potential of a single one-off treatment with long-term effect on chronic B-cell-/microglia-driven neuroinflammation and accompanied neurodegeneration, representing a real game-changer in the future management of MS. This evidence concerns the gene TNFRSF17 and myeloid sarcoma.